Details for Patent: 8,552,002
✉ Email this page to a colleague
Which drugs does patent 8,552,002 protect, and when does it expire?
Patent 8,552,002 protects TRUSELTIQ and is included in one NDA.
This patent has forty-five patent family members in thirty-one countries.
Summary for Patent: 8,552,002
| Title: | Compounds and compositions as protein kinase inhibitors |
| Abstract: | The invention relates to compounds of formula (I) ##STR00001## wherein the substituents X.sup.1, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease. |
| Inventor(s): | Ding; Qiang (Beijing, CN), Gray; Nathanael Schiander (Boston, MA), Li; Bing (Northborough, MA), Liu; Yi (San Diego, CA), Sim; Taebo (Seoul, KR), Uno; Tetsuo (San Diego, CA), Zhang; Guobao (San Diego, CA), Pissot Soldermann; Carole (Village-Neuf, FR), Breitenstein; Werner (Basel, CH), Bold; Guido (Gipf-Oberfrick, CH), Caravatti; Giorgio (Bottmingen, CH), Furet; Pascal (Thann, FR), Guagnano; Vito (Basel, CH), Lang; Marc (Mulhouse, FR), Manley; Paul William (Basel, CH), Schoepfer; Joseph (Riehen, CH), Spanka; Carsten (Lorrach, DE) |
| Assignee: | Novartis AG (Basel, CH) IRM LLC (Hamilton, BM) |
| Application Number: | 11/570,983 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,552,002
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-002 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,552,002
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0512324.5 | Jun 16, 2005 |
| PCT Information | |||
| PCT Filed | June 23, 2005 | PCT Application Number: | PCT/EP2005/006815 |
| PCT Publication Date: | January 05, 2006 | PCT Publication Number: | WO2006/000420 |
International Family Members for US Patent 8,552,002
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 050343 | ⤷ Try a Trial | |||
| Austria | E520671 | ⤷ Try a Trial | |||
| Australia | 2005256491 | ⤷ Try a Trial | |||
| Australia | 2009213036 | ⤷ Try a Trial | |||
| Brazil | PI0512588 | ⤷ Try a Trial | |||
| Canada | 2570873 | ⤷ Try a Trial | |||
| China | 101035769 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
